BIOMAT Database Logo BIOMAT Database Logo

The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. 1987

J A Kelley, and C L Litterst, and J S Roth, and D T Vistica, and D G Poplack, and D A Cooney, and M Nadkarni, and F M Balis, and S Broder, and D G Johns
Laboratory of Pharmacology and Experimental Therapeutics, National Cancer Institute, Bethesda, MD 20892.

The pharmacokinetics and metabolism of the anti-human T-lymphotrophic virus type III/lymphadenopathy-associated virus agent 2',3-dideoxycytidine have been examined in BDF1 mice and rhesus monkeys, with ancillary enzyme studies carried out on tissue derived from both the latter species and also from human subjects. For the pharmacokinetic studies, 2',3-dideoxycytidine and its catabolic product 2',3-dideoxyuridine have been separated and measured in plasma, urine, and cerebrospinal fluid by a reverse HPLC method. For metabolic studies, tritium-labeled drug (labeled in the 5- and 6-positions of the pyrimidine ring) has been employed, utilizing an ion exchange HPLC analytical method suitable for the separation of the parent nucleoside from its mono-, di-, and triphosphates in cell extracts and in tissue homogenates. The drug is rapidly cleared from plasma in a biphasic manner (terminal t 1/2 in BDF1 mice and rhesus monkeys of 67 min and 109 min, respectively) following an iv bolus dose of 325 mg/m2. This two-compartment open model is predictive of plasma concentrations during long term ip infusions in mice. Dideoxycytidine is predominantly excreted in the urine as unchanged parent compound, although a minor urinary metabolite (2,3-dideoxyuridine) is detected in the monkey but not in the mouse. Oral absorption of 2',3'-dideoxycytidine is rapid, with plasma levels approaching those seen after iv administration within 45 min in the mouse. Entry to the central nervous system is also rapid, but the cerebrospinal fluid to plasma AUC ratio after iv administration is only 0.026-0.040 in rhesus monkeys.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008253 Macaca mulatta A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans. Chinese Rhesus Macaques,Macaca mulatta lasiota,Monkey, Rhesus,Rhesus Monkey,Rhesus Macaque,Chinese Rhesus Macaque,Macaca mulatta lasiotas,Macaque, Rhesus,Rhesus Macaque, Chinese,Rhesus Macaques,Rhesus Macaques, Chinese,Rhesus Monkeys
D008297 Male Males
D003564 Cytidine Deaminase An enzyme that catalyzes the deamination of cytidine, forming uridine. EC 3.5.4.5. Cytidine Aminohydrolase,Aminohydrolase, Cytidine,Deaminase, Cytidine
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

J A Kelley, and C L Litterst, and J S Roth, and D T Vistica, and D G Poplack, and D A Cooney, and M Nadkarni, and F M Balis, and S Broder, and D G Johns
In vitro toxicity and metabolism of 2',3'-dideoxycytidine, an inhibitor of human immunodeficiency virus infectivity.
January 1991, Chemico-biological interactions,
J A Kelley, and C L Litterst, and J S Roth, and D T Vistica, and D G Poplack, and D A Cooney, and M Nadkarni, and F M Balis, and S Broder, and D G Johns
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.
March 1986, Proceedings of the National Academy of Sciences of the United States of America,
J A Kelley, and C L Litterst, and J S Roth, and D T Vistica, and D G Poplack, and D A Cooney, and M Nadkarni, and F M Balis, and S Broder, and D G Johns
Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.
July 1986, Biochemical pharmacology,
J A Kelley, and C L Litterst, and J S Roth, and D T Vistica, and D G Poplack, and D A Cooney, and M Nadkarni, and F M Balis, and S Broder, and D G Johns
Pharmacodynamics of 2',3'-dideoxycytidine: an inhibitor of human immunodeficiency virus.
May 1990, The American journal of medicine,
J A Kelley, and C L Litterst, and J S Roth, and D T Vistica, and D G Poplack, and D A Cooney, and M Nadkarni, and F M Balis, and S Broder, and D G Johns
Cellular metabolism of 2',3'-dideoxycytidine, a compound active against human immunodeficiency virus in vitro.
January 1987, The Journal of biological chemistry,
J A Kelley, and C L Litterst, and J S Roth, and D T Vistica, and D G Poplack, and D A Cooney, and M Nadkarni, and F M Balis, and S Broder, and D G Johns
Human red blood cells as bioreactors for the release of 2',3'-dideoxycytidine, an inhibitor of HIV infectivity.
October 1989, Biochemical and biophysical research communications,
J A Kelley, and C L Litterst, and J S Roth, and D T Vistica, and D G Poplack, and D A Cooney, and M Nadkarni, and F M Balis, and S Broder, and D G Johns
Control of hepatitis B and human T lymphotrophic virus type III (HTLV-III) in homosexuals in Sheffield.
June 1986, Genitourinary medicine,
J A Kelley, and C L Litterst, and J S Roth, and D T Vistica, and D G Poplack, and D A Cooney, and M Nadkarni, and F M Balis, and S Broder, and D G Johns
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
October 1985, Proceedings of the National Academy of Sciences of the United States of America,
J A Kelley, and C L Litterst, and J S Roth, and D T Vistica, and D G Poplack, and D A Cooney, and M Nadkarni, and F M Balis, and S Broder, and D G Johns
Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys.
February 1992, Pharmaceutical research,
J A Kelley, and C L Litterst, and J S Roth, and D T Vistica, and D G Poplack, and D A Cooney, and M Nadkarni, and F M Balis, and S Broder, and D G Johns
Human T-lymphotrophic virus type I and multiple sclerosis.
June 1990, Annals of neurology,
Copied contents to your clipboard!